You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行报告》大和上调维亚生物(01873.HK)目标价至10.9元 评级「买入」
阿思达克 11-16 14:30
大和发表报告指,维亚生物(01873.HK)公布完成收购内地药品合同开发和制造商(CDMO)朗华制药股权,集团将合并朗华今年11月及12月的财务业绩。

该行表示,下一步是观望朗华能否达到收购协议中今年1.6亿元人民币的保证盈利,预期该公司能达到此目标。大和早前估计集团仅能合并朗华今年12月的业绩,由於合并期改变,上调维亚生物今年收入预测21.1%,由6.31亿元升至7.64亿元人民币,盈利预测亦上调13.4%,最新估计集团今年至2022年的核心盈利年均复合增长率可达90%。

大和又上调维亚生物股份目标价,由10.4元升至10.9元,评级维持「买入」。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account